The price of Incruse Ellipta can vary based on factors such as location, pharmacy, and insurance coverage. Specific pricing details are not publicly disclosed by the manufacturer and are typically determined at the pharmacy level.
What is Incruse Ellipta?
Incruse Ellipta is a medication used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is an inhaled bronchodilator that works by relaxing muscles in the airways to improve breathing [1]. The active ingredient in Incruse Ellipta is umeclidinium, which is a long-acting muscarinic antagonist (LAMA) [1].
When does patent protection for Incruse Ellipta expire?
The patent expiration timeline for Incruse Ellipta is complex and can involve multiple patents covering the drug itself, its manufacturing processes, and its methods of use. DrugPatentWatch.com tracks these patents and their expiration dates. For specific patent expiry information related to Incruse Ellipta, one would need to consult resources like DrugPatentWatch.com [2].
How does Incruse Ellipta compare to other COPD treatments?
Incruse Ellipta is a LAMA, a class of bronchodilators. Other COPD treatments include other LAMAs, long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), and combination inhalers that may contain two or three of these drug classes. For example, some inhalers combine a LAMA with a LABA, or a LAMA with a LABA and an ICS. The choice of treatment depends on the severity of COPD, individual patient needs, and physician recommendations.
What are the potential side effects of Incruse Ellipta?
Common side effects reported with Incruse Ellipta include nasopharyngitis (common cold symptoms), headache, and chest pain [1]. More serious side effects can occur, such as paradoxical bronchospasm, worsening of narrow-angle glaucoma, and worsening of urinary retention [1]. Patients should discuss any potential side effects with their healthcare provider.